Similarly, the CHECKMATE-649 trial showed that nivolumab, in combination with chemotherapy, improved OS in advanced GC and EGJ cancers compared to chemotherapy alone, particularly in cases where PD-L1 CPS was five or higher [63]. The gene discussed is CD274; the disease is gastric cancer.